Please assess the completion status of the following clinical trial:

Trial Title: A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of CF~* Homozygous for the F508del CFTR mutation~* Forced expiratory volume in 1 second (FEV1) greater than or equal to (\>=) 40 percent (%) and less than or equal to (=\<) 90% of predicted normal for age, sex, and height~* Willing to remain on a stable CF medication regimen through Week 24 or, if applicable, the Safety Follow up Visit~Exclusion Criteria:~* An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease within 4 weeks before first dose of study drug~* History of solid organ or hematological transplantation~* History of alcohol or drug abuse in the past year~* Ongoing or prior participation in an investigational drug study (including studies investigating lumacaftor and/or ivacaftor) within 30 days of screening.~* Use of strong inhibitors, moderate inducers, or strong inducers of Cytochrome P450 3A (CYP3A) within 14 days before Day 1 of dosing

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matched to lumacaftor (LUM, VX-809) and ivacaftor (IVA, VX-770) tablet every 12 hours (q12h), up to Week 24.
- LUM 600 mg qd/IVA 250 mg q12h (Type: EXPERIMENTAL): LUM 600 milligram (mg) plus IVA 250 mg fixed-dose combination (FDC) tablet in the morning and IVA 250 mg film-coated tablet in the evening, up to Week 24.
- LUM 400 mg q12h/ IVA 250 mg q12h (Type: EXPERIMENTAL): LUM 400 mg plus IVA 250 mg FDC tablet in the morning and in the evening, up to Week 24.

Based on this trial design, predict the completion outcome and termination type (if applicable).